Aquestive Therapeutics, Inc. (AQST)
4.59
-0.02
(-0.43%)
USD |
NASDAQ |
Oct 07, 09:48
Aquestive Therapeutics Net Income (Quarterly) : -22.86M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -22.86M |
| March 31, 2026 | -8.057M |
| December 31, 2025 | -31.86M |
| September 30, 2025 | -15.45M |
| June 30, 2025 | -13.55M |
| March 31, 2025 | -22.93M |
| December 31, 2024 | -17.06M |
| September 30, 2024 | -11.51M |
| June 30, 2024 | -2.745M |
| March 31, 2024 | -12.83M |
| December 31, 2023 | -8.111M |
| September 30, 2023 | -2.035M |
| June 30, 2023 | -5.792M |
| March 31, 2023 | 8.068M |
| December 31, 2022 | -12.35M |
| September 30, 2022 | -12.54M |
| June 30, 2022 | -16.30M |
| March 31, 2022 | -13.22M |
| December 31, 2021 | -28.94M |
| Date | Value |
|---|---|
| September 30, 2021 | -14.56M |
| June 30, 2021 | -12.37M |
| March 31, 2021 | -14.67M |
| December 31, 2020 | -20.37M |
| September 30, 2020 | -16.55M |
| June 30, 2020 | -2.334M |
| March 31, 2020 | -16.53M |
| December 31, 2019 | -12.64M |
| September 30, 2019 | -18.41M |
| June 30, 2019 | -20.47M |
| March 31, 2019 | -14.73M |
| December 31, 2018 | -13.94M |
| September 30, 2018 | -15.04M |
| June 30, 2018 | -36.49M |
| March 31, 2018 | 4.099M |
| December 31, 2017 | -10.04M |
| September 30, 2017 | 8.451M |
| June 30, 2017 | -5.897M |
| March 31, 2017 | -1.457M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| LENZ Therapeutics, Inc. | -31.92M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 5.534B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 13.82M |
| Total Expenses (Quarterly) | 36.68M |
| EPS Diluted (Quarterly) | -0.1829 |
| Enterprise Value | 629.20M |
| Gross Profit Margin (Quarterly) | 70.93% |
| Profit Margin (Quarterly) | -165.5% |
| Earnings Yield | -14.15% |
| Normalized Earnings Yield | -12.73 |